Physician profile
Nayan Mainkar
NPI 1023672862
$3,083.17
in general payments reported to CMS, 2019-2025
21 companies · $461 in 2025
The $461 reported for 2025 was more than what 77% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $114 · 2022: $412 · 2023: $1,024 · 2024: $1,073 · 2025: $461.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,149 · Education: $409.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,148.55 |
| Education | $408.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $772.02 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $642.18 | 2022-2025 | Keytruda, Lynparza, Welireg |
| Incyte Corporation | $381.37 | 2023-2025 | Jakafi, Pemazyre, Monjuvi |
| Regeneron Healthcare Solutions, INC. | $240.42 | 2021-2025 | Libtayo |
| Seagen INC. | $224.98 | 2022-2023 | |
| Alexion Pharmaceuticals, INC. | $198.94 | 2022-2024 | Ultomiris |
| Sobi, INC | $125.00 | 2022 | |
| Tempus Ai, INC | $101.59 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $66.88 | 2023-2024 | Enhertu, Imfinzi |
| Pfizer INC. | $56.70 | 2023-2024 | |
| Abbvie INC. | $47.41 | 2023-2024 | |
| Exelixis INC. | $47.16 | 2024-2025 | Cabometyx |
| Astellas Pharma US INC | $27.56 | 2023 | Cresemba |
| E.R. Squibb & Sons, L.L.C. | $26.48 | 2023-2024 | Augtyro, Opdivo |
| Amgen INC. | $21.33 | 2023 | Blincyto, Kyprolis |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $20.07 | 2024 | Orgovyx |
| Janssen Biotech, INC. | $19.36 | 2024 | Rybrevant |
| Daiichi Sankyo INC. | $18.16 | 2024 | Vanflyta |
| Array Biopharma INC | $16.41 | 2024 | Tukysa, Braftovi, Mektovi |
| Adc Therapeutics America, INC. | $14.73 | 2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.42 | 2024 | Xifaxan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nayan Mainkar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.